title: Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.
abstract: BACKGROUND
  Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are given in combination.
  
  
  METHODS
  This unexpected effect is rationalized through computer models and molecular dynamic simulations by hypothesizing that the two antibodies can co-localize on the same molecule of the Her2 extracellular domain.
  
  
  RESULTS
  Simulations suggest that the clinical synergism observed for the two antibodies arises partly from enhanced affinity that originates in cooperative interactions between these two antibodies when they are co-localized on Her2 and "clamp" it; this may inhibit dimerization and possibly higher oligomerizations with neighboring receptors. In the presence of trastuzumab, the receptor becomes highly plastic, especially domains I to III, and this appears to promote increased association with pertuzumab. Further, the presence of pertuzumab evokes novel interactions between the receptor and trastuzumab. Indeed, splicing out of this region in silico results in a big reduction in the interactions of the antibody with the receptor.
  
  
  CONCLUSIONS
  If validated, these findings will bring about a new direction in the design of antibodies whereby different epitopes on the same antibody may be targeted to lead to synergistic/cooperative inhibition and contribute to generate more potent therapeutics and to increase clinical efficacy.
authors: Bioinformatics Institute, A*STAR, Singapore. gfuentes@bii.a-star.edu.sg
authors: Gloria
authors: G
authors: Fuentes
authors: Maurizio
authors: M
authors: Scaltriti
authors: José
authors: J
authors: Baselga
authors: Chandra S
authors: CS
authors: Verma
references: J Clin Oncol. 2010 Mar 1;28(7):1138-44
references: 20124182
references: Oncogene. 2009 Jan 22;28(3):461-8
references: 18978815
references: Biochemistry. 2009 Sep 8;48(35):8435-48
references: 19627157
references: Breast Cancer Res Treat. 2010 Jul;122(1):35-43
references: 19701706
references: Cancer Cell. 2004 Apr;5(4):317-28
references: 15093539
references: Proteins. 1998 Feb 1;30(2):144-54
references: 9489922
references: J Struct Biol. 2009 Aug;167(2):117-28
references: 19406245
references: J Mol Biol. 2003 Jul 18;330(4):891-913
references: 12850155
references: Biopolymers. 1984 Jun;23(6):1099-112
references: 6733249
references: Mol Cancer Ther. 2010 Sep;9(9):2593-604
references: 20716637
references: Oncogene. 2000 Dec 11;19(53):6102-14
references: 11156523
references: Acc Chem Res. 2000 Dec;33(12):889-97
references: 11123888
references: Phys Rev E Stat Nonlin Soft Matter Phys. 2007 Nov;76(5 Pt 1):051918
references: 18233698
references: Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70
references: 10482195
references: Biochemistry. 2010 May 4;49(17):3575-92
references: 20230061
references: Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W665-7
references: 15215472
references: Nature. 2003 Feb 13;421(6924):756-60
references: 12610629
references: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references: 11252954
references: FEBS J. 2008 Oct;275(20):4967-79
references: 18795950
references: N Engl J Med. 1987 Oct 8;317(15):955-7
references: 3627214
references: Cell. 2010 Sep 3;142(5):699-713
references: 20813259
references: Proteins. 1993 Dec;17(4):412-25
references: 8108382
references: Bioinformatics. 2006 Nov 1;22(21):2695-6
references: 16940322
references: Nat Rev Cancer. 2009 Jul;9(7):463-75
references: 19536107
references: Science. 1989 May 12;244(4905):707-12
references: 2470152
references: Cell. 2000 Oct 13;103(2):211-25
references: 11057895
references: Mol Cell. 2003 Feb;11(2):495-505
references: 12620236
references: Exp Cell Res. 2003 Mar 10;284(1):31-53
references: 12648464
references: Annu Rev Pharmacol Toxicol. 2004;44:195-217
references: 14744244
references: Curr Opin Mol Ther. 2010 Jun;12(3):340-9
references: 20521223